A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy

J Allergy Clin Immunol. 2011 May;127(5):1309-10.e1. doi: 10.1016/j.jaci.2011.01.051. Epub 2011 Mar 11.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Allergens / administration & dosage*
  • Antibodies, Anti-Idiotypic / administration & dosage
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Arachis / immunology*
  • Child
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Omalizumab
  • Peanut Hypersensitivity / immunology
  • Peanut Hypersensitivity / therapy*
  • Plant Proteins / administration & dosage*
  • Plant Proteins / immunology
  • Treatment Outcome
  • Young Adult

Substances

  • Allergens
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Plant Proteins
  • Omalizumab